Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2011 Summary Slides Worldwide SUM-WW11_1.ppt.

Slides:

Advertisements

Similar presentations

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2012 Summary Slides SUM12_1.ppt.

Advertisements

Who, What and When: Transplant for Acute Lymphoblastic Leukemia Brandon Hayes-Lattin September 13, 2013.

Hematopoietic Stem Cell Transplantation Lynn Savoie September 30, 2006.

Congenital Neutropenia: Making the Decision to Transplant John E. Levine, MD, MS University of Michigan Blood and Marrow Transplantation Program.

Hematopoietic Cell Transplant (HCT) in Older Individuals Keith M. Sullivan, MD Duke University Medical Center ASBMT Corporate Retreat September 2012.

Hematopoietic stem cell transplantation

Blood and marrow stem cell transplantation A.Basi ADULT HEMATOLOGIST,ONCOLOGIST IRAN UNIVERSITY OF MEDICAL SCIENCES.

Hematopoietic Stem Cell Transplantation (HSCT) Overview Willis H Navarro, MD Medical Director, Transplant Services, NMDP Associate Clinical Professor,

CHIMERISM & DLI Dr. Serdar ŞIVGIN Kayseri Feb, 2011.

The role of transplant for CML in the imatinib era Dr Wendy Ingram Consultant Haematologist University Hospital of Wales.

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2010 CIBMTR Summary Slides SUM10_1.ppt.

Acute Myeloid Leukemia

DR. YETUNDE T. ISRAEL-AINA PAEDIATRICIAN, UNIVERSITY OF BENIN TEACHING HOSPITAL, BENIN CITY BENIN BLOOD AND MARROW TRANSPLANT WORKSHOP, UNIVERSITY OF BENIN.

林建廷 April 28,  IPSS for MDS (FAB classification) ◦ Greenberg P et al. International scoring system for evaluating prognosis in myelodysplastic.

Supplementary Table 1. Impact of pretransplant factors on the incidence of pulmonary complications FactorUnivariate RR (95% CI)P-valueMultivariate RR *1.

Hematopoietic stem cell transplantation- HSCT. Principle of HSCT Myeloablation and eradication of residual disease with hogh dose conditioning regimen.

5-Azacitidine For Myelodysplasia Before Allogeneic Hematopoietic Cell Transplantation Field T et al. Bone Marrow Transplant 2009:[Epub ahead of print].

Transplant Creations1 Treatment & Transplant Program to improve disease outcome Transplant Creations Marlies Van Hoef.

DONOR LYMPHOCYTE INFUS I ON (DLI) Dr. Serdar ŞIVGIN February 2011 Kayseri.

Allogeneic “Mini” Transplantation Mark B. Juckett M.D. June 4, 2004.

Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) for Relapsed/Refractory Hodgkin Lymphoma (HL) in the Brentuximab.

Optimizing Timing of Transplant in Hodgkin Lymphoma Ginna G. Laport, MD Associate Professor of Medicine Division of Blood & Marrow Transplantation Stanford.

Table 1.1.1: Stock and Flow of Blood and Marrow Transplantation, Year New transplant patients Deaths

HEART-LUNG TRANSPLANTATION Pediatric Recipients 2015 JHLT Oct; 34(10):

N ATIONAL M ARROW D ONOR P ROGRAM ® Entrusted to operate the C.W. Bill Young Cell Transplantation Program, including the Be The Match Registry SM Advances.

Table 1.1.1: Stock and Flow of Blood and Marrow Transplantation, Year New transplant patients Deaths

Daunorubicin VS Mitoxantrone VS Idarubicin As Induction and Consolidation Chemotherapy for Adults with Acute Myeloid Leukemia : The EORTC and GIMEMA Groups.

Hematopoietic Stem Cell Current Status and Future Directions

Hematopoietic Stem Cell Transplantation (HSCT)

Margaret L. Green, Wendy M. Leisenring, Hu Xie, Roland B. Walter, Marco Mielcarek, Brenda M. Sandmaier, Stanley R. Riddell and Michael Boeckh Blood NUM.

New Approaches for Transplant Patients Linda J Burns, MD Medical Director, Health Services Research Program National Marrow Donor Program (NMDP)/Be the.

Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors N Engl J Med 2012;367: R3 Sunhee park/Prof. Kyung-sam cho.

Factors Predictive of Relapse of Acute Leukemia in Children after Allogeneic Hematopoietic Cell Transplantation Nirali N. Shah, Michael J. Borowitz,

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2010 CIBMTR Summary Slides INTRODUCTION: The Summary Slides are an annual report.

Supplemental table 1 Patients' characteristics Variables Number

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation

Current Uses and Outcomes of Hematopoietic Cell Transplantation (HCT)

Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen.

Allogeneic stem cell transplantation (allo-SCT) is a potentially curative procedure for a variety of malignant and nonmalignant conditions. Historically,

EBMT Activity Survey Teams 39,313 Patients 43,636 Transplants

Center Specific Outcomes Reporting

Gupta V, Tallman MS, Weisdorf DJ

EBMT Activity Survey Teams Patients Transplants

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.

Mohamed A. Kharfan-Dabaja, Claudio Anasetti, Edgardo S. Santos

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved Nicolas Novitzky,

PREDICTIVE FACTORS AFFECTING THE OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION USING RIC REGIMENS: EXPERIENCE FROM A SINGLE CENTRE Dott.ssa M. Medeot.

by Jayesh Mehta Blood Volume 112(2): July 15, 2008

Assessment of Allogeneic HCT in Older Patients with AML and MDS: A CIBMTR Analysis McClune B et al. ASCO/ASH Symposium 2009;The Best of ASH Special & Plenary.

ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION for MULTIPLE MYELOMA

Reduced-Intensity Allogeneic Stem Cell Transplantation in Adults and Children with Malignant and Nonmalignant Diseases: End of the Beginning and Future.

Twenty Years of Unrelated Donor Hematopoietic Cell Transplantation for Adult Recipients Facilitated by the National Marrow Donor Program Chatchada Karanes,

Hematopoietic Stem Cell Transplantation for Patients with AML

Comparison of Outcomes after HLA-Matched Sibling and Unrelated Donor Transplantation for Children with High-Risk Acute Lymphoblastic Leukemia Mei-Jie.

Table 1.1.1: Stock and Flow of Blood and Marrow Transplantation,

Comparison of Cord Blood Transplantation with Unrelated Bone Marrow Transplantation in Patients Older than Fifty Years Masatsugu Tanaka, Koichi Miyamura,

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.

Twenty Years of Unrelated Donor Bone Marrow Transplantation for Pediatric Acute Leukemia Facilitated by the National Marrow Donor Program Margaret L.

Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation Betul Oran, John E. Wagner, Todd.

Cutaneous Complications in Hematopoietic Cell Transplant Recipients: Impact of Biopsy on Patient Management Oana Paun, Tycel Phillips, Pingfu Fu, Roberto.

Transplantation Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents with Acute Lymphoblastic.

Hematopoietic Cell Transplantation for Children with Acute Lymphoblastic Leukemia in Second Complete Remission: Similar Outcomes in Recipients of Unrelated.

High Alloreactivity of Low-Dose Prophylactic Donor Lymphocyte Infusion in Patients with Acute Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.

Introduction. Title: Activities and Outcomes of Hematopoietic Cell Transplantation in Japan.

Mohamed A. Kharfan-Dabaja, Yasser R. Abou Mourad, Hugo F

Clinical Lymphoma, Myeloma and Leukemia

Factors Predictive of Relapse of Acute Leukemia in Children after Allogeneic Hematopoietic Cell Transplantation Nirali N. Shah, Michael J. Borowitz,

Transplants Facilitated by NMDP/Be The Match

Survival after HLA-Matched Sibling Donor HCT for ALL, Age ≥18 Years,

Presentation transcript:

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2011 Summary Slides Worldwide SUM-WW11_1.ppt

Location of Centers participating in the CIBMTR 2011 SUM-WW11_2.ppt Slide

Transplants SUM11_41.ppt Slide 3 Transplant Activity in the U.S

SUM-WW11_3.ppt Allogeneic Stem Cell Sources by Recipient Age Age 20 yrsAge 20 yrs Slide 4 Transplants, %

SUM-WW11_4.ppt Autologous Stem Cell Sources by Recipient Age Age 20 yrsAge 20 yrs Slide 5 Transplants, %

SUM-WW11_5.ppt Trends in Transplants by Type and Recipient Age* * Transplants for AML, ALL, NHL, Hodgkin Disease, Multiple Myeloma Slide 6 Transplants, % Allogeneic TransplantsAutologous Transplants

SUM11_5.ppt Trends in Transplants by Transplant Type and Recipient Age* * Transplants for AML, ALL, NHL, Hodgkin Disease, Multiple Myeloma Slide 7 Transplants, % Allogeneic TransplantsAutologous Transplants

Indications for Hematopoietic Stem Cell Transplants in the United States, 2009 SUM-WW11_8.ppt Slide 8 Number of Transplants

Indications for Hematopoietic Stem Cell Transplants for Age 20yrs in the United States, 2009 SUM-WW11_9.ppt Slide 9 Number of Transplants

SUM-WW11_10.ppt Allogeneic Transplants for Age 20yrs, Registered with the CIBMTR by Donor Type and Graft Source - Slide 10 Number of Transplants * * Data incomplete

SUM-WW11_11.ppt Allogeneic Transplants for Age 20yrs, Registered with the CIBMTR by Donor Type and Graft Source - Slide 11 Number of Transplants * * Data incomplete

SUM-WW11_12.ppt Unrelated Donor Stem Cell Sources by Recipient Age Age 20 yrsAge 20 yrs Slide 12 Transplants, %

SUM-WW11_13.ppt Unrelated Cord Blood Transplants, by Age Registered with the CIBMTR Slide 13 Number of Transplants * * Data incomplete

One-year survival after myeloablative conditioning for acute leukemias in any remission phase, CML or MDS, age 50 years, by year of transplant and graft source, One-Year Survival, % SUM11_40.ppt Slide 14

SUM-WW11_14.ppt 100-day Mortality after Autologous Transplants, Slide 15 Mortality, %

SUM-WW11_15.ppt 100-day Mortality after HLA-identical Sibling Transplants, Slide 16 Early Disease Intermediate Disease Advanced Disease Chronic Phase Accelerated Phase Blast Phase Other Mortality, %

SUM-WW11_16.ppt 100-day Mortality after Unrelated Donor Transplants, Slide 17 Early Disease Intermediate Disease Advanced Disease Chronic Phase Accelerated Phase Blast Phase Other Mortality, %

Causes of Death after Transplants performed in Autologous Infection (8%) Other (16%) Organ Failure (2%) New Malignancy (1%) Primary Disease (73%) Unrelated Donor Infection (16%) Other (29%) Organ Failure (6%) Primary Disease (33%) New Malignancy (1%) GVHD (15%) SUM-WW11_17.ppt Slide 18 HLA-identical Sibling Infection (12%) Other (21%) Primary Disease (47%) GVHD (14%) Organ Failure (4%) New Malignancy (1%)

SUM-WW11_18.ppt Allogeneic Transplants, Registered with the CIBMTR, by Conditioning Regimen Intensity & Age - * * Data incomplete Slide 19 Number of Transplants

SUM-WW11_19.ppt Allogeneic Transplants after Reduced- intensity Conditioning, by Donor Type, Registered with CIBMTR * * Data incomplete Slide 20 Number of Transplants

Years Probability of Survival after HLA-identical Sibling Donor Transplants for AML By Disease Status - Early (N=6,317) Intermediate (N=1,675) Advanced (N=2,645) Probability of Survival, % P < SUM-WW11_20.ppt Slide 21

Years Probability of Survival after Unrelated Donor Transplants for AML, By Disease Status - Early (N=4,260) Intermediate (N=2,864) Advanced (N=3,173) Probability of Survival, % P < SUM-WW11_21.ppt Slide 22

Years Probability of Survival after HLA-identical Sibling Donor Transplants for AML, Age 20yrs, by Disease Status - Early (N=1,176) Intermediate (N=239) Advanced (N=250) Probability of Survival, % P < SUM-WW11_22.ppt Slide 23

Years Probability of Survival after Autologous Transplants for AML, by Disease Status - Early (N=1,979) Intermediate (N=672) Advanced (N=139) Probability of Survival, % P < SUM-WW11_23.ppt Slide 24

Years Probability of Survival after Allogeneic Transplants for MDS by Disease Status and Donor Type Probability of Survival, % P < SUM-WW11_24.ppt Slide 25 Early, sibling donor (N=667) Early, unrelated donor (N=752) Advanced, sibling donor (N=1,188) Advanced, unrelated donor (N=1,400)

Years Probability of Survival after HLA-identical Sibling Donor Transplants for ALL, Age 20yrs by Disease Status Probability of Survival, % P < SUM-WW11_25.ppt Slide 26 Early (N=777) Intermediate (N=1,092) Advanced (N=196)

Years Probability of Survival after Unrelated Donor Transplants for ALL, Age 20yrs, By Disease Status Probability of Survival, % P < SUM-WW11_26.ppt Slide 27 Intermediate (N=1,832) Advanced (N=278) Early (N=848)

Years Probability of Survival after HLA-identical Sibling Donor Transplants for ALL, Age 20yrs, By Disease Status Probability of Survival, % P < SUM11_27.ppt Slide 28 Intermediate (N=627) Advanced (N=568) Early (N=1,918)

Years Probability of Survival after Unrelated Donor Transplants for ALL, Age 20yrs, By Disease Status Probability of Survival, % P < SUM-WW11_28.ppt Slide 29 Intermediate (N=928) Advanced (N=700) Early (N=1,458)

Years Probability of Survival after HLA-identical Sibling Donor Transplants for CML, By Disease Status and Transplant Year Probability of Survival, % P < SUM-WW11_29.ppt Slide 30 CP, (N=2,291) AP, (N=300) CP, (N=2,524) AP, (N=333)

Years Probability of Survival after Autologous and HLA- matched Sibling Donor Hematopoietic Cell Transplantation for CLL, by Donor Type and Conditioning Regimen Intensity Probability of Survival, % P < SUM-WW11_29.ppt Slide 31 Autologous transplant (N=253) Myeloablative conditioning(N=425) Reduced-intensity conditioning (N=752)

Years Probability of Survival after Allogeneic Transplants for SAA, By Donor Type and Age Probability of Survival, % P < SUM-WW11_31.ppt Slide 32  20y, Sibling Donor (N=1,191)  20y, Sibling Donor (N=1,256)  20y, Unrelated Donor (N=574)  20y, Unrelated Donor (N=550)

Years Probability of Survival after Autologous Transplants for Hodgkin Disease, By Disease Status Probability of Survival, % P < SUM-WW11_32.ppt Slide 33 CR (N=2,419) Not in CR, sensitive (N=2,826) Not in CR, resistant (N=642)

Years Probability of Survival after Allogeneic Transplants for Hodgkin Disease, By Donor Type Probability of Survival, % P < SUM-WW11_33.ppt Slide 34 Sibling Donor (N=302) Unrelated Donor (N=183)

Years Probability of Survival after Autologous Transplants for Follicular Lymphoma, By Disease Status Probability of Survival, % P < SUM-WW11_34.ppt Slide 35 Sensitive (N=2,030) Resistant (N=172)

Years Probability of Survival after HLA-identical Sibling Donor Transplants for Follicular Lymphoma, By Disease Status Probability of Survival, % P < SUM-WW11_35.ppt Slide 36 Sensitive (N=698) Resistant (N=144)

Years Probability of Survival after Autologous Transplants for Diffuse Large B-Cell Lymphoma, By Disease Status Probability of Survival, % P < SUM-WW11_36.ppt Slide 37 Sensitive (N=6,337) Resistant (N=453)

Years Probability of Survival after Allogeneic Transplants for Diffuse Large B-Cell Lymphoma, By Disease Status Probability of Survival, % P < SUM-WW11_37.ppt Slide 38 Sensitive (N=383) Resistant (N=124)

Years Probability of Survival after Transplants for Mantle Cell Lymphoma, By Donor Type Probability of Survival, % P < SUM-WW11_38.ppt Slide 39 Sibling donor (N=498) Unrelated donor (N=325) Autologous (N=2,574)

Years Probability of Survival after Transplants for Multiple Myeloma, By Donor Type Probability of Survival, % P < SUM-WW11_39.ppt Slide 40 Sibling Donor (N=827) Unrelated donor (N=470) Autologous (N=23,197)